{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dmards/management/baricitinib/","result":{"pageContext":{"chapter":{"id":"cff5fc6d-3554-5bf8-832a-c8a089699b6f","slug":"baricitinib","fullItemName":"Scenario: Baricitinib","depth":2,"htmlHeader":"<!-- begin field 28eb842e-c203-4887-8b28-a7ee00a4d27b --><h2>Scenario: Baricitinib</h2><!-- end field 28eb842e-c203-4887-8b28-a7ee00a4d27b -->","summary":"Covers the monitoring of baricitinib in adults in primary care.","htmlStringContent":"<!-- begin item f4d1e78d-1f75-4295-95c6-a7ee00a4cf4c --><!-- begin field 29d2340d-f40c-4745-8547-acbc015c27a5 --><p>From age 18 years onwards.</p><!-- end field 29d2340d-f40c-4745-8547-acbc015c27a5 --><!-- end item f4d1e78d-1f75-4295-95c6-a7ee00a4cf4c -->","topic":{"id":"493980c0-c660-5bda-b643-f98644c1eff8","topicId":"caed8aa7-f8ba-4a46-9441-92701c2ad78a","topicName":"DMARDs","slug":"dmards","lastRevised":"Last revised in April 2020","chapters":[{"id":"d587cd65-a186-50e3-a192-8d3f3b5c074b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e4b02852-ea41-536a-8ec9-462ecfc95b24","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"189d2086-77a0-57a3-84ed-6f44f1e56879","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ff583a6c-57af-5ded-8488-19039e0cd272","slug":"changes","fullItemName":"Changes"},{"id":"d65ec114-ec65-504e-a69b-b4fef29f3ca6","slug":"update","fullItemName":"Update"}]},{"id":"c02019ed-342b-5aa7-a645-a8c979fa0d56","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"0ee8d208-7733-5a7d-928a-41e080d05756","slug":"goals","fullItemName":"Goals"},{"id":"2206fe89-030d-5fec-adf5-ee4a379ff3a0","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca18e3ee-b448-5d95-b060-d5ab2e909dd2","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ce5c5664-0c85-52e9-b3d1-835fa7e52c8f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ac9bf99d-b5d4-5d63-8e5c-bb174916417e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2c23a774-3e76-52d5-8316-b8cbe2060151","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"33f76ef2-b579-5b80-985a-587d2f7cbb17","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"13df5021-0440-5dfe-b200-6910e116b50b","slug":"indications","fullItemName":"Indications"}]},{"id":"f919120c-d8c9-5fb7-b29a-fe422146fc29","fullItemName":"Management","slug":"management","subChapters":[{"id":"a22ece65-e42d-59b8-82a9-4633e64a7441","slug":"general-principles-of-managing-dmards","fullItemName":"Scenario: General principles of managing DMARDs"},{"id":"7428c7c0-3189-5d82-8d3c-61151fc43773","slug":"apremilast","fullItemName":"Scenario: Apremilast"},{"id":"c241c22b-6dd4-5334-b240-a532f0f78fd7","slug":"azathioprine","fullItemName":"Scenario: Azathioprine"},{"id":"cff5fc6d-3554-5bf8-832a-c8a089699b6f","slug":"baricitinib","fullItemName":"Scenario: Baricitinib"},{"id":"fc4f9786-0db2-5fcd-a2ca-589807093e6a","slug":"biologics","fullItemName":"Scenario: Biologics"},{"id":"a8c361a4-0693-5e57-a935-24a8383a76ba","slug":"ciclosporin","fullItemName":"Scenario: Ciclosporin"},{"id":"92b93974-10b7-5147-b0cb-e21d187093e4","slug":"cyclophosphamide","fullItemName":"Scenario: Cyclophosphamide"},{"id":"928496d4-4642-55d5-98fe-86bd350c2913","slug":"gold-intramuscular","fullItemName":"Scenario: Gold - intramuscular"},{"id":"bed27174-d641-5a3b-958e-fdb3f1b0c33f","slug":"hydroxychloroquine","fullItemName":"Scenario: Hydroxychloroquine"},{"id":"b87df30d-4917-58a4-84b5-2db454410a88","slug":"leflunomide","fullItemName":"Scenario: Leflunomide"},{"id":"29f64422-8646-5cd9-ab79-c6919331e041","slug":"methotrexate","fullItemName":"Scenario: Methotrexate"},{"id":"c4758020-9fa5-5122-9cd7-c871ebd54d73","slug":"mycophenolate-mofetil-mmf","fullItemName":"Scenario: Mycophenolate mofetil (MMF)"},{"id":"5870b3d5-8b5b-5029-86fa-0f688b740005","slug":"penicillamine","fullItemName":"Scenario: Penicillamine"},{"id":"7b2bca14-9fd5-55c7-9a3f-bb044a5c53cb","slug":"sulfasalazine","fullItemName":"Scenario: Sulfasalazine"},{"id":"4fddf07b-12b6-51d6-93db-59bb536a2db1","slug":"tacrolimus","fullItemName":"Scenario: Tacrolimus"},{"id":"1dcd6206-8d6f-548c-a253-fc19d5deb6e7","slug":"tofacitinib","fullItemName":"Scenario: Tofacitinib"},{"id":"6e4b7cba-f4a1-5221-9b40-b3adeaf750bc","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"0fcf14f9-de6c-5f14-b7e2-222e952f6aa4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5bcf1ebc-c823-5866-8643-bb3a12bd2e78","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"99f1248a-29fc-5534-8f2a-306820d31914","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"92a3e377-bfa8-5bcb-92d5-38bd17e970e8","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bb2fda74-5193-58b7-9e0b-40e6129a4629","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"65080272-e93d-5ccb-a5f0-bcecaca6aae1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"44895091-401a-5a9b-b11f-a4e952ec6de2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"caffbaca-bd54-566b-921b-c2363a59a842","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f919120c-d8c9-5fb7-b29a-fe422146fc29","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"93583354-d306-5019-bcee-dbcfad6925f5","slug":"baricitinib-monitoring-requirements","fullItemName":"Baricitinib monitoring requirements","depth":3,"htmlHeader":"<!-- begin field d891372f-97b6-4ccf-b610-a7ee00a4d28d --><h3>What monitoring is required for baricitinib?</h3><!-- end field d891372f-97b6-4ccf-b610-a7ee00a4d28d -->","summary":null,"htmlStringContent":"<!-- begin item 016648d3-96ec-44ac-82e0-a7ee00a4d28d --><!-- begin field dd430b49-5767-4ca8-bf84-a7ee00a4d28d --><ul><li>People who are starting treatment with a baricitinib should be screened for active and latent tuberculosis (TB) before starting treatment. In addition, they should be monitored closely for infectious diseases including TB before, during, and after treatment for six months.</li><li>For information on when to refer people on baricitinib, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/dmards/management/general-principles-of-managing-dmards/#when-to-refer\">when to refer</a>.</li></ul><p><strong>Table 2.</strong> Primary care monitoring requirements for people on baricitinib.</p><table><thead><tr><th colspan=\"1\">Monitoring</th><th colspan=\"1\">Frequency</th></tr></thead><tbody><tr><td colspan=\"1\">Full Blood Count (FBC)</td><td colspan=\"1\" rowspan=\"3\"><ul><li>Every 2 weeks until dose is stable for 6 weeks. </li><li>Then monthly for 3 months.</li><li>Thereafter, at least every 12 weeks.<ul><li>More frequent monitoring is appropriate in patients at higher risk of toxicity</li></ul></li><li><strong>Dose increases:</strong> Every 2 weeks until dose is stable for 6 weeks, then revert to previous schedule.</li></ul></td></tr><tr><td colspan=\"1\">Creatinine/calculated GFR<sup>* </sup></td></tr><tr><td colspan=\"1\">Liver Function Tests (LFTs): ALT and/or AST and albumin</td></tr><tr><td colspan=\"1\">Lipid profile</td><td colspan=\"1\"><ul><li>Monitor lipids 12 weeks after treatment started, then monitor periodically.<ul><li>Hyperlipidaemia should be managed according to clinical guidelines.</li></ul></li></ul></td></tr><tr><td colspan=\"1\">Tuberculosis</td><td colspan=\"1\"><ul><li>If clinically indicated.</li></ul></td></tr><tr><td colspan=\"2\">AST, aspartate transaminase; ALT, alanine aminotransferase; GFR, glomerular filtration rate. *This has been extrapolated from the monitoring requirements for other non-biologic DMARDs</td></tr><tr><td colspan=\"2\"><strong>Data from: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ACR, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">BSR, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017c</a>]</td></tr></tbody></table><!-- end field dd430b49-5767-4ca8-bf84-a7ee00a4d28d --><!-- end item 016648d3-96ec-44ac-82e0-a7ee00a4d28d -->","subChapters":[{"id":"43f511fa-714f-56da-bfff-9343af01bb32","slug":"basis-for-recommendation-5a1","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 841d9489-25b8-4ea5-9d9d-a7ee00a4d292 --><h4>Basis for recommendation</h4><!-- end field 841d9489-25b8-4ea5-9d9d-a7ee00a4d292 -->","summary":null,"htmlStringContent":"<!-- begin item 5a153c6d-d58d-45f0-916a-a7ee00a4d292 --><!-- begin field b4679975-6af1-426b-a7ae-a7ee00a4d292 --><p>These recommendations are based on the manufacturer's Summary of Product Characteristics for Olumiant [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017c</a>], the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">BNF 73, 2017</a>], the American College of Rheumatology (ACR) <em>Guideline for the treatment of rheumatoid arthritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ACR, 2015</a>], and extrapolated from the British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) <em>BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">BSR, 2017</a>], which details requirements for other non-biologic DMARDs.</p><h5>Tuberculosis (TB) screening</h5><ul><li>The recommendation to screen for TB is extrapolated from an American College of Rheumatology recommendation for tofacitinib, which advises that the same TB screening algorithm used for biologics should be used for tofacitinib [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ACR, 2015</a>].</li></ul><h5>Creatinine/GFR </h5><ul><li>CKS could find no specific guidance to indicate that creatinine/GFR needs to be monitored. This is a pragmatic recommendation, based on what Prodgy consider good clinical practice. </li></ul><h5>Frequency of monitoring</h5><ul><li>CKS could find no specific guidance on the frequency of monitoring for baricitinib.</li><li>The manufacturer's Summary of Product Characteristics advises that monitoring should occur according to routine management [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017c</a>].</li><li>CKS considers that in the absence of specific guidance that the monitoring frequency for other DMARDs may be appropriate for baricitinib, however local shared care agreements should be followed if they differ.</li></ul><!-- end field b4679975-6af1-426b-a7ae-a7ee00a4d292 --><!-- end item 5a153c6d-d58d-45f0-916a-a7ee00a4d292 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}